Otonomy 'successfully' completes Phase 2 clinical trial of Otiprio
Otonomy announced the successful completion of a Phase 2 clinical trial that evaluated a single administration of Otiprio for the treatment of pediatric patients with acute otitis media with tympanostomy tubes, or AOMT. The Phase 2 trial was designed to evaluate the safety and tolerability of two dose levels of Otiprio, 6 mg and 12 mg, administered in pediatric patients with AOMT and to determine the most appropriate dose for further development in this indication. The trial demonstrated that both Otiprio doses were well-tolerated, achieved higher and statistically significant clinical cure rates over sham, with the highest clinical cure rate observed in the 12 mg dose group. Additional results from this trial will be presented at the Otonomy Investor and Analyst Day on October 7 and will be presented at an upcoming medical conference.